GT BIOPHARMA, INC. Debt Securities, Available-for-sale, Unrealized Loss
GT BIOPHARMA, INC. (GTBP) reported Debt Securities, Available-for-sale, Unrealized Loss of $2.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2024-05-15
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-03-31 was $2.00K, a 93.10% decline year-over-year.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2023-03-31 was $29.00K.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-12-31 was -$23.00K.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $30.00K, a 3.45% increase from fiscal 2021.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized loss for fiscal 2021 was $29.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2024-03-31 | $2.00K 10-Q · filed 2024-05-15 | |||
| 2023-03-31 | $29.00K 10-Q · filed 2023-05-15 | $6.00K derived: sum of 2 quarters · filed 2024-03-26 | ||
| 2022-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $30.00K 10-K · filed 2024-03-26 | ||
| 2022-09-30 | $53.00K 10-Q · filed 2022-10-31 | |||
| 2021-12-31 | $29.00K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |